Radiopharmaceutical shows promise after Pluvicto; Vera Therapeutics gains FDA agreement to speed IgA nephropathy data analysis

A new radiopharmaceutical is generating interest for use after patients have completed Pluvicto therapy, suggesting a potential follow‑on treatment option.

Abivax reported encouraging results from its ulcerative colitis study, adding to the company’s pipeline momentum.

Fulcrum Therapeutics announced that it is discontinuing development of its sickle‑cell disease candidate, citing strategic considerations.

The FDA and Vera Therapeutics reached a pact that lets the company begin analysis of its confirmatory Phase 3 trial of atacicept for IgA nephropathy in the third quarter, ahead of the original timeline. The drug is already under review for accelerated approval, with a final decision expected by July 7.